NASDAQ
205.10USD
+0.01 (+0.00%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
31B
P/E
—
EPS
—
Beta
1.47
52W range
88-205.93
Day range
192.84–205.94
Open
203.33
Prev close
205.09
Volume
4.1M
Avg volume
1.9M
Dividend
0.00
IPO
2000-07-28
https://www.fool.com/investing/2026/08/01/is-gral-a-buy-sell-or-hold-at-70/ · 8/1/2026+0.00
https://www.etftrends.com/disruptive-technology-content-hub/robo-vs-botz-etf-a-comparison-for-portfolios/ · 7/23/2026+0.00
https://www.zacks.com/stock/news/2956493/3-promising-genomics-stocks-to-add-to-your-portfolio-in-2026?cid=CS-STOCKNEWSAPI-FT-genomics_&_synthetic_biology-2956493 · 7/20/2026+0.50
https://www.zacks.com/stock/news/2938681/why-illumina-ilmn-is-a-top-momentum-stock-for-the-long-term?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|zacks_education_momentum_score-2938681 · 6/17/2026+0.00
https://www.prnewswire.com/news-releases/volta-labs-brings-the-complete-twist-hybrid-capture-portfolio-to-callisto-with-launch-of-twist-fast-hyb-302798837.html · 6/12/2026+0.10
https://www.marketbeat.com/instant-alerts/caredx-highlights-39-q1-growth-naveris-oncology-push-at-jefferies-2026-06-07/ · 6/7/2026+0.20
https://www.zacks.com/stock/news/2915878/why-illumina-ilmn-is-a-top-momentum-stock-for-the-long-term?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|zacks_education_momentum_score-2915878 · 5/6/2026+0.00
https://www.zacks.com/stock/news/2915002/pacbio-pre-q1-analysis-time-to-buy-hold-or-sell-the-stock-now?cid=CS-STOCKNEWSAPI-FT-analyst_blog|earnings_preview-2915002 · 5/5/2026+0.10
https://www.zacks.com/stock/news/2912496/tempus-ai-vs-illumina-which-oncology-stock-is-worth-buying-now?cid=CS-STOCKNEWSAPI-FT-analyst_blog|most_popular_stocks-2912496 · 4/30/2026+0.40
https://www.defenseworld.net/2026/04/25/cwm-llc-grows-stake-in-ishares-sp-mid-cap-400-value-etf-ijj.html · 4/25/2026+0.30
https://www.zacks.com/stock/news/2898433/will-illumina-ilmn-beat-estimates-again-in-its-next-earnings-report · 4/10/2026+0.80
https://seekingalpha.com/article/4889717-illumina-competitive-threats-priced-in · 4/10/2026+0.60
Illumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies. The company's offerings empower clients across various sectors to integrate genomic insights into both research and clinical environments, with applications spanning critical fields like life sciences, cancer diagnostics, reproductive health, agriculture, and innovative new domains. Illumina's portfolio encompasses specialized instrumentation and necessary consumables for genetic analysis, alongside comprehensive genotyping and sequencing services. They also offer instrument maintenance agreements, collaborate through development and licensing deals, and perform cancer detection tests. Its diverse clientele comprises leading genomic research facilities, universities, state-funded laboratories, medical centers, pharmaceutical and biotechnology firms, commercial molecular diagnostic providers, and businesses focused on consumer genomics. Illumina employs a two-pronged distribution strategy, selling directly to clients across North America, Europe, Latin America, and the Asia-Pacific. Additionally, it partners with life-science distributors to reach markets in Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. Established in 1998, the company maintains its corporate headquarters in San Diego, California.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
